Market revenue in 2023 | USD 35.8 million |
Market revenue in 2030 | USD 47.6 million |
Growth rate | 4.2% (CAGR from 2023 to 2030) |
Largest segment | Outpatient facilities |
Fastest growing segment | Home Care |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Hospitals, Outpatient Facilities, Home Care, Research & Manufacturing |
Key market players worldwide | Thermo Fisher Scientific Inc, Qiagen NV, Illumina Inc, Roche Holding AG ADR, BD, Agilent Technologies Inc, Myriad Genetics Inc, Koninklijke Philips NV, Abbott Laboratories, Hitachi Ltd, Danaher Corp, Prestige Medical |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to pancreatic cancer diagnostic market will help companies and investors design strategic landscapes.
Outpatient facilities was the largest segment with a revenue share of 63.97% in 2023. Horizon Databook has segmented the Norway pancreatic cancer diagnostic market based on hospitals, outpatient facilities, home care, research & manufacturing covering the revenue growth of each sub-segment from 2018 to 2030.
In December 2021, Illumina supported Norway’s IMPRESS-Norway study to evaluate blood-based Comprehensive Genomic Profiling (CGP) for cancer therapy selection. The study compares blood samples with solid tissue biopsies to assess if CGP from blood can effectively identify genetic changes relevant to treatment choices, potentially replacing invasive tissue sampling.
This approach aims to expand patient access to therapy-matching and clinical trials. Illumina’s DRAGEN software will analyze CGP results across Norway’s pathology network (InPreD), enhancing precision diagnostics. This initiative underscores Illumina’s role in advancing genomic technologies for personalized cancer care and improving patient outcomes.
This advancement could lead to earlier identification of genetic mutations and biomarkers associated with pancreatic cancer, facilitating more targeted and effective treatment strategies. Moreover, expanded access to therapy-matching and clinical trials through CGP could accelerate R&D in pancreatic cancer diagnostics, ultimately improving patient outcomes and driving innovation in the market.
Horizon Databook provides a detailed overview of country-level data and insights on the Norway pancreatic cancer diagnostic market , including forecasts for subscribers. This country databook contains high-level insights into Norway pancreatic cancer diagnostic market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account